The G protein-coupled receptor APJ is a promising therapeutic target for heart failure.
Constitutive deletion of APJ in the mouse is protective against the hypertrophy-heart failure …

Background Apelin, the endogenous ligand for the G protein-coupled apelin receptor, is an
important regulator of the cardiovascular homoeostasis. We previously demonstrated that …

Apelin is the endogenous ligand for the previously orphaned G protein-coupled receptor,
APJ. This novel peptidic signalling pathway is widely represented in the heart and …

Studies have shown significant cardiovascular effects of exogenous apelin administration,
including the potent activation of cardiac contraction. However, the role of the endogenous …

Apelin interacts with the APJ receptor to enhance inotropy. In heart failure, apelin-APJ
coupling may provide a means of enhancing myocardial function. The alterations in apelin …

Signaling by the peptide ligand apelin and its cognate G protein-coupled receptor APJ has a
potent inotropic effect on cardiac contractility and modulates systemic vascular resistance …

Cardiac hypertrophy is initiated as an adaptive response to sustained overload but
progresses pathologically as heart failure ensues. Here we report that genetic loss of APJ, a …

It has recently been demonstrated that the apelin receptor (APJ) plays a significant role in
mediating the stretch response within the heart in a G-protein-independent and β-arrestin …

Background: Apelin and its cognate G protein-coupled receptor, APJ, constitute a signaling
pathway with a positive inotropic effect on cardiac function. Recently, we and other …

Apelin, the endogenous ligand for the G-protein-coupled APJ receptor, is emerging as a key
hormone in cardiovascular homoeostasis. It is expressed in a diverse range of tissues with …